CTKB
Cytek Biosciences, Inc.
CTKB's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over CTKB overall, supported by stronger fundamentals and lower modeled downside.
CTKB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
CTKB's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CTKB PE Valuation
CTKB has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CTKB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CTKB's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CTKB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.64 | -$0.54 |
| Q2 2026 | -$0.63 | -$0.58 |
| Q1 2026 | -$0.58 | -$0.49 |
| Q4 2025 | -$0.52 | -$0.47 |
| Q3 2025 | -$0.10 | -$0.02 |
| Q2 2025 | -$0.05 | +$0.09 |
| Q1 2025 | -$0.09 | $0.00 |
| Q4 2024 | -$0.05 | +$0.04 |
CTKB lost $0.64 per share over the past year, and its loss has widened in each of the last five quarters.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CTKB on earnings quality, reporting a profit while its opponent remains loss making.
CTKB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $53.2M | +1.8% |
| Q2 2026 | $48.1M | +5.6% |
| Q1 2026 | $44.1M | +6.5% |
| Q4 2025 | $62.1M | +8.1% |
| Q3 2025 | $52.3M | +1.5% |
| Q2 2025 | $45.6M | -2.2% |
| Q1 2025 | $41.5M | -7.6% |
| Q4 2024 | $57.5M | -1.3% |
CTKB's revenue has grown year over year for five quarters in a row: $53M last quarter, up 1.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -16% | +1.8 points |
| Q2 2026 | -24% | -0.4 points |
| Q1 2026 | -42% | -5.7 points |
| Q4 2025 | -9% | -14 points |
| Q3 2025 | -18% | -9.3 points |
| Q2 2025 | -23% | -5 points |
| Q1 2025 | -36% | -12 points |
| Q4 2024 | 5.2% | +5.4 points |
CTKB's operating margin was −16% last quarter, up 1.8 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CTKB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CTKB on profitability, with a higher operating margin.
CTKB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6M | -$1.4M |
| Q2 2026 | -$849K | +$620K |
| Q1 2026 | -$4.9M | -$3.9M |
| Q4 2025 | -$1.8M | -261% |
| Q3 2025 | -$4.6M | -137% |
| Q2 2025 | -$1.5M | -129% |
| Q1 2025 | -$974K | -129% |
| Q4 2024 | $1.1M | -86% |
CTKB has burned cash in seven of the last eight quarters: −$13M over the past year, against −$6M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CTKB on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTKB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +898K shares |
| 1 year | +2.2% | +2.8M shares |
| 3 years | -4.3% | -5.8M shares |
| 5 years | +260% | +94.2M shares |
| Available history | +6% | +7.3M shares |
CTKB has 130M diluted shares, up 2.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $34,000 |
| Q3 2025 | $29,000 |
| Q2 2025 | $4.5M |
| Q1 2025 | $10.6M |
| Q4 2024 | $7M |
CTKB has spent almost nothing on buybacks in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CTKB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CTKB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -431.1x | Net Cash |
| Q3 2022 | -185.1x | Net Cash |
| Q2 2022 | -100.0x | Net Cash |
| Q1 2022 | -48.1x | Net Cash |
| Q4 2021 | -37.2x | Net Cash |
| Q3 2021 | -23.1x | Net Cash |
| Q2 2021 | -7.9x | Net Cash |
| Q1 2021 | -10.0x | Net Cash |
CTKB has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CTKB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.6 | Neutral |
| Stochastic | 77.2 | Neutral |
CTKB's weekly RSI is 57 (neutral) and its Stochastic is 77 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CTKB PE vs Healthcare Sector
| Metric | CTKB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTKB has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CTKB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.66 | 2.5% below |
| 20 week MA | $5.04 | 9.5% above |
| 50 week MA | $4.73 | 17% above |
| 100 week MA | $4.50 | 23% above |
| 200 week MA | $5.95 | 7.2% below |
CTKB's trend is mixed: it's above three of its five weekly moving averages, and 7.2% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CTKB on trend strength, trading above more of its moving averages.
CTKB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.8 | $17.3 | -8% |
| 2022 | $17.3 | $10.1 | -41% |
| 2023 | $10.1 | $9.12 | -9.9% |
| 2024 | $9.12 | $6.39 | -30% |
| 2025 | $6.39 | $5.10 | -20% |
| 2026 YTD | $5.10 | $5.52 | +8.2% |
CTKB has finished every year since 2021 lower, and it's up 8.2% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CTKB on returns for 2026, with the stronger performance.